

17 June 2026

By email: [listingscompliancemelbourne@asx.com.au](mailto:listingscompliancemelbourne@asx.com.au)

Dear Sir/Madam

**INOVIQ Limited ACN 009 070 384 (ASX Code: IIQ) – ASX Price Query Response**

In response to the ASX Price Query letter dated 17 June 2026 the company responds to your questions as follows:

- (1) No.
- (2) Not applicable.
- (3) IIQ notes that earlier today, a third party published a research note on IIQ's investment thesis and upcoming catalysts. This note drew attention to previously announced upcoming milestones for its EXO-OC test clinical study results and also *in vitro* CAR-exosome ovarian cancer data targeted for completion by the end of June 2026 which may have contributed to heightened investor awareness and activity.

As confirmed in the IIQ March 2026 quarterly update, 'INOVIQ is advancing an expanded clinical study in approximately 2,000 biobanked plasma samples to further demonstrate the accuracy and robustness of EXO-OC™. This large, blinded, retrospective case-control study is evaluating test performance (*sensitivity, specificity and Area Under the Receiver Operating Curve; AUC*) across different ovarian cancer stages, high-risk groups and confounding diseases including non-ovarian cancers, endometriosis, uterine fibroids, diabetes and other inflammatory conditions. Sample analysis commenced in April 2026, and the study remains on track for completion of the ovarian cancer-control group in June 2026, representing a major near-term inflection point for the Company. Analysis of the high-risk and confounding disease groups will follow in H2 CY2026'.

- (4) The Company confirms that it is complying with the Listing Rules and in particular, Listing Rule 3.1.
- (5) The Company confirms that IIQ's responses to the questions above have been authorised by its Board.

If you have any queries, please contact me.

Yours faithfully



Mark Edwards  
Company Secretary  
INOVIQ Limited  
Ph: (03) 9548 7586

17 June 2026

Mr Mark Edwards  
Company Secretary  
Inoviq Limited  
23 Normandy Road, Notting Hill VIC 3168

By email: medwards@inoviq.com

Dear Mr Edwards

### **Inoviq Limited ('IIQ'): Price Query**

ASX refers to the following:

A. The change in the price of IIQ's securities from a close of \$0.295 on 16/06/2026 to a high of \$0.365 today.

### **Request for information**

In light of this, ASX asks IIQ to respond separately to each of the following questions and requests for information:

1. Is IIQ aware of any information concerning it that has not been announced to the market which, if known by
2. If the answer to question 1 is "yes".
  - (a) Is IIQ relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in IIQ's securities would suggest to ASX that such information may have ceased to be confidential and therefore IIQ may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that IIQ may have for the recent trading in its securities?
4. Please confirm that IIQ is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that IIQ's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of IIQ with delegated authority from the board to respond to ASX on disclosure matters.

### **When and where to send your response**

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **4.00 PM AEST Wednesday, 17 June 2026**.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, IIQ's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require IIQ to request a trading halt immediately.

For personal use only

---

Your response should be sent by e-mail to **ListingsComplianceMelbourne@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow us to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### **Trading halt**

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is “yes” and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in IIQ’s securities under Listing Rule 17.1. If you wish to request a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts and Voluntary Suspensions*.

### **Suspension**

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in IIQ’s securities under Listing Rule 17.3.1.

### **Listing Rules 3.1 and 3.1A**

In responding to this letter, you should have regard to IIQ’s obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*. It should be noted that IIQ’s obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### **Release of correspondence between ASX and entity**

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A. The usual course is for correspondence to be released to the market.

Kind regards

---

ASX Compliance